Sign in
WithdrawnPhase 2

SNIFF - 3-Week Aptar CPS Device

Key facts

Who runs it
Wake Forest University Health Sciences
Trial code
Status
Withdrawn
Phase
Phase 2
Started
May 2025
Expected to end
May 2031
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Insulin (Humulin® R U-100)
  • Placebo
  • Aptar Pharma CPS Intranasal Delivery Device
Record updated
28 July 2025
Why it stopped
protocol being rewritten and submitted as new study

Who can take part

Age
55 years to 85 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age 55 to 85 (inclusive)
  • Fluent in English
  • Cognitively normal or diagnosis of amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD)
  • Amyloid positive by positron emission tomography (PET) or cerebrospinal fluid (CSF) criteria
  • Stable medical condition for 3 months prior to screening visit
  • Stable medications for 4 weeks prior to the screening and study visits (exceptions may be made on a case by case basis by the study physician)
  • Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the study physician

Who cannot take part

  • Current or past regular use of insulin or any other anti-diabetic medication within 2 months of screening visit
  • Use of an investigational agent within two months of screening visit
  • Regular use of alcohol, narcotics, anticonvulsants, anti-parkinsonian medications, or any other exclusionary medications (exceptions may be made on a case by case basis by the study physician)
  • A diagnosis of dementia other than Alzheimer's disease (AD)
  • History of a clinically significant stroke
  • Current evidence or history in past two years of epilepsy, head injury with loss of consciousness, any major psychiatric disorder including psychosis, major depression, bipolar disorder
  • Diabetes (type I or type II) insulin-dependent and non-insulin-dependent diabetes mellitus
  • History of seizure within past five years
  • Pregnancy or possible pregnancy
  • Use of anticoagulants
  • Residence in a skilled nursing facility at screening

About the trial

What the trial wants to find out

The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. This study is measuring how much insulin the device delivers. In addition, this study will look at the effects of insulin or placebo administered intra-nasally using an intranasal delivery device on memory, blood, and cerebrospinal fluid (CSF).

The 2 groups in the trial

  • Humulin® R U-100Treatment being tested

    Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of Humulin® R U-100 (40 IU) four times daily for 3 weeks.

    Treatment: Insulin (Humulin® R U-100) and Aptar Pharma CPS Intranasal Delivery Device

  • PlaceboPlacebo, for comparison

    Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of placebo (insulin diluent) four times daily for 3 weeks.

    Treatment: Placebo and Aptar Pharma CPS Intranasal Delivery Device

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Study of Nasal Insulin to Fight Forgetfulness (SNIFF) - 3-Week Aptar CPS Device
Record updated
28 July 2025